Zydus Lifesciences has informed that it enclosed a copy of press release dated October 3, 2022 titled - Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets.
The above information is a part of company’s filings submitted to BSE.